Data on target organ protection, blood glucose levels, blood pressure, weight, insulin usage, and adverse events (AEs) associated with Sotagliflozin in the treatment of T1D were collected from databases including PubMed, Scopus, Web of Science, Embase, and the Cochrane Library. This evidence concerns the gene INS and type 1 diabetes mellitus.